custirsen + cabazitaxel + prednisone

This is a **combination regimen** of *custirsen*, *cabazitaxel*, and *prednisone* developed and studied for the treatment of **metastatic castration-resistant prostate cancer** (mCRPC) previously treated with docetaxel. - **Custirsen (OGX-011)** is a second-generation antisense oligonucleotide designed to inhibit the production of clusterin, a cytoprotective, antiapoptotic protein upregulated in response to anticancer therapies and involved in treatment resistance[1][3][4]. - **Cabazitaxel** is a microtubule inhibitor chemotherapy (a taxane derivative) used in prostate cancer[1][2]. - **Prednisone** is a synthetic glucocorticoid used to reduce inflammation and as part of combination regimens in oncology. The regimen was tested in the phase 3 AFFINITY trial and did **not demonstrate added survival benefit** compared to cabazitaxel and prednisone alone for patients with mCRPC; adverse events were more frequent in the triplet therapy[1][2][4].